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Chapter 1 
Introduction 
Lipodystrophy  
Lipodystrophy is a condition caused by fat deficiency where adipose cells 
are destroyed or barely present (1). The disease exists in genetic and acquired 
forms, the former being very rare. Congenital generalized lipodystrophy (the 
Seip-Berardinelli syndrome) and the familial partial lipodystrophies (the Dunnigan 
type, the Kobberling type and the mandibuloacral dysplasia type) are the genetic 
forms. Acquired partial lipodystrophy (the Barraquer- Simons syndrome), 
acquired generalized lipodystrophy (the Lawrence syndrome) and protease 
inhibitors-induced lipodystrophy (HIV treatment) are the acquired forms. HIV 
related lipodystrophies are observed in about 50% of HIV patients, being the 
most common form of lipodystrophy (2). 
There exist two methods through which dysfunctional adipose tissue may 
play a role in metabolic disease: the first is the reduced capability to store 
triglycerides which in turn leads to an increase in the levels of circulating fat as 
well as the deposition of excess lipids in non-adipose tissues. The second is 
anomalies in the production of hormones and adipokines. In lipodystrophic or 
obesity-mediated metabolically ill patients, these two pathways typically occur 
concurrently, rendering it hard to determine the mechanistic and/or pathogenic 
determinants of these disorders (3).  
These patients also suffer from other anomalies including 
hypertriglyceridemia along with insulin resistance and type II diabetes (4), which 
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in turn lead to further complications: severe hypertriglyceridemia eventually 
causes recurrent acute pancreatitis attacks, and severe hyperglycemia increases 
the risk for diabetic nephropathy and retinopathy. They also develop 
steatohepatitis which may lead to cirrhosis (5).   
Treatment Modalities for Lipodystrophy 
The major characteristics of lipodystrophy, insulin resistance and 
hypertriglyceridemia are usually managed by multiple drugs including lipid-
lowering medications along with insulin therapy and/or oral hypoglycemics (5); 
however, they have been so far resistant to treatment (6). Thiazolidinediones 
have been shown to be an effective therapy, yet not the perfect one (7). Other 
treatment modalities have also been attempted. For instance, Wanke et al 
treated 10 HIV-induced lipodystrophy patients with Recombinant Human Growth 
Hormone (rhGH) for 3 months and found that this short-term rhGH treatment was 
an effective therapy for the body shape alterations that accompany the syndrome 
(8).  
Leptin replacement therapy, so far, seems to be the most effective therapy 
for lipodystrophic patients. This was first demonstrated in 2002 by Oral et al in 
studies where they administered recombinant leptin subcutaneously to nine 
lipodystrophic patients over four months. This treatment resulted in an 
improvement in glycemic control, a decrease in triglyceride levels and a reduction 
in liver volume, as well as decreased food intake and resting energy expenditure 
(5). Similarly, Simha et al found in 2003 that leptin replacement therapy reduced 
intramyocellular and intrahepatic lipid content in three such patients (9). The 
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reduced food intake, decreased energy expenditure and reduced liver volume in 
response to leptin treatment were further demonstrated by Moran et al in 2004 
(10). Javor et al tested the long-term efficacy of leptin treatment in 15 
lipodystrophic patients for 12 months. They also found, in 2005, that leptin 
administration led to marked improvements in glycemia, dyslipidemia and hepatic 
steatosis (estimated by liver volume), announcing leptin as the first effective long-
term treatment for severe lipodsytrophy (11). Ebihara et al confirmed in 2007 that 
leptin administered to generalized lipodystrophy patients improves insulin 
sensitivity as well as lipid metabolism (12).  
What is Leptin? 
Being a triglyceride storage depot and an endocrine tissue, white adipose 
tissue plays an important role in energy metabolism as well as lipid and glucose 
homeostasis. The adipocytes from white adipose tissue produce hormones that 
regulate food intake and metabolism, mainly leptin and adiponectin (13). The 
adipocyte-derived hormone leptin was discovered in 1994 by Zhang et al as a 
protein product of a defective gene in the ob/ob mouse (14). Leptin plays a major 
role in food intake and energy expenditure regulation (15), as it is known to 
reduce food intake and increase metabolism. Several studies have shown that its 
administration to leptin-deficient and normal rodents results in patent reductions 
in food intake, body weight and body fat. The obese population, on the other 
hand, has elevated leptin and does not appear to benefit from leptin therapy, a 
concept typically called “leptin resistance” (16).  
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Leptin receptors, through which leptin regulates energy homeostasis, are 
expressed in the hypothalamus (17) and many peripheral tissues (18). The levels 
of regulation vary: Fatty acid oxidation (19) and glucose uptake in skeletal 
muscle cells (20) are stimulated by leptin, whereas hepatic gluconeogenesis and 
lipogenesis are inhibited by leptin (21, 22). Leptin reduces pancreatic B-cell 
production of insulin (23) and also enhances insulin action (24), which is thought 
to be controlled via a cascade of reactions (25). Leptin's effect on glucose and 
lipid metabolism and insulin sensitivity appears to be mostly independent of its 
regulation of food intake (26). However, various pathways are known to mediate 
its metabolic effects. For instance, leptin represses the gene stearoyl-CoA 
desaturase-1 (SCD-1) which plays a role in leptin-induced metabolic changes 
(27). Leptin also plays a role in growth and reproduction (28), inflammation, 
hematopoiesis (29) and immunity (28, 29). 
Hyperleptinemia is commonly seen in obese patients revealing increased 
adiposity and leptin resistance. This profile may contribute to the hypertension, 
impaired glucose metabolism, and pro-atherogenic condition in obese and 
metabolic syndrome patients (30). 
Mouse Models of Lipodystrophy 
Excess adiposity in obesity and lack of adipose tissue in lipodystrophy are 
both often coupled with insulin resistance and related complications. Strangely 
enough, lipodystrophy shares similar metabolic abnormalities with obesity. For 
treating lipodystrophy-related metabolic disorders, leptin replacement therapy is 
a successful approach, yet it does not appear promising in the treatment of 
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complications associated with obesity (31). However, a well-controlled genetically 
modified lipodystrophy mouse model can help unravel these mechanisms and 
also find therapeutic targets for treating/preventing the metabolic syndrome/ 
metabolic abnormalities related to obesity (3). Mouse models of lipodystrophy are 
very useful in the sense that they may help understand these mechanisms and 
possibly uncover new pharmaceutical targets for managing metabolic disorders 
associated with dysfunctional adipose tissue (31). 
Inducible, late onset and early onset mouse models of lipodystrophy have 
been developed. There are two known inducible models: 1- Fat apoptosis 
through targeted activation of caspase 8 (FAT-ATTAC) mice that are transgenic 
mice suffering from adipose tissue ablation resulting from treatment with a 
chemical dimerizer (32); and 2- Protease inhibitor-induced lipodystrophic mice 
(3).  
There are two late onset models as well: 1- aP2-diphteria toxin A mice 
which are born with a normal phenotype but develop adipose tissue atrophy at 
five to six months of age (33); and 2- Ribosomal S6 kinase 2 knockout mice 
which display partial fat loss, reduced leptin levels, insulin resistance and a 
propensity for liver steatosis (34).  
There exist eight known early onset models: 1- The aP2-SREBP-1c 
mouse is a transgenic mouse model of lipodystrophy expressing an active form 
of the SREBP-1c transcription factor in its adipose tissue, causing remarkably 
reduced body fat, hepatic steatosis, insulin resistance, hyperglycemia, 
hypertriglyceridemia and enlarged organs (35). 2- Mox2-Cre-floxed PPARγ 
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knockout mice are PPARγ deficient mice that are lipodystrophic and insulin 
resistant. Only a small percentage of these mice survive until adulthood (36). 3- 
Adipose-specific PPARγ knockout mice have only a small amount of adipose 
tissue with decreased adipokine concentration. In addition, the adipose tissue 
they have appears prone to inflammation. These mice also have elevated blood 
lipids and a propensity for hepatic steatosis and insulin resistance (37). 4- 
PPARγ-2 knockout mice are more viable than the PPARγ knockout mice, but 
also have markedly reduced adipose tissue and circulating adipokines (38). 5- 
PPARγ hypomorphic mice are PPARγ-1 deficient due to an alteration in a 
PPARγ-2-specific exon. These mice also have markedly reduced body fat (39). 
6- PPARγ P465L mice were made to mimic human patients with the dominant 
negative PPARγ P465L mutation who experience partial lipodystrophy, liver 
steatosis, altered lipid metabolism, insulin resistance and hypertension (40). 7- 
Fatty liver dystrophy mice are generated from a lipin1 gene mutation and are also 
lipodystrophic (41). 8- Last but not least, the A-ZIP/F-1 mouse is a transgenic 
mouse that lacks white adipose tissue for life via expressing the AZIP/F protein 
(42).  
The AZIP/F-1 Lipodystrophic Mouse 
The AZIP/F-1 mouse was produced by adipose-selective expression of a 
dominant-negative form of the transcription factor C/EBPα thus expressing the A-
ZIP/F protein, under the control of the adipose-specific aP2 enhancer/promoter. 
C/EBPα normally regulates adipocyte differentiation. A-ZIP/F prevents the DNA 
binding of B-ZIP transcription factors of the C/EBP and Jun families. The mice 
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therefore have little to no white adipose tissue throughout life and minimal 
amounts of brown adipose tissue (42).  
They firstly encounter delayed development that is then caught up by 
week 12 when their body weight exceeds that of their non-transgenic littermates. 
They are also characterized by reduced fertility. They have severe hepatic 
steatosis as well as enlarged organs in general. They tend to develop type II 
diabetes as they are hyperinsulinemic (50- to 400-fold) at 1 week of age and 
hyperglycemic (3-fold) by 4 weeks of age. They have reduced leptin levels (20-
fold) and increased free fatty acids (2-fold) and triglycerides (3- to 5-fold). They 
are finally polyphagic, polydipsic and polyuric (42). 
The phenotype of AZIP/F-1 mice is very similar to that of patients with 
severe lipoatrophic diabetes (1). The A-ZIP/F-1 phenotype therefore may serve 
as a mouse model for human lipoatrophic diabetes (Seip-Berardinelli syndrome), 
where the lack of fat contributes to a diabetic phenotype. According to the 
authors, this model would help tackle the numerous drawbacks of lacking fat 
throughout growth (42).  
General Characteristics of Fatless Mice 
The syndrome observed in lipoatrophic mice is markedly comparable to 
that of lipoatrophic diabetes patients (43). AZIP mice, for instance, have nearly 
no white adipose tissue, which results in hyperglycemia, insulin resistance, 
hyperlipidemia, elevated liver triglycerides and hepatomegaly (44, 45). As it is 
very well known, insulin resistance is the common precursor to type II diabetes 
(46) and impairments in fat metabolism may promote insulin resistance (47, 48). 
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Kim et al postulated that insulin resistance in the AZIP fatless mice may be 
attributed to triglyceride accumulation in the liver and muscle due to the lack of 
adipose tissue, which in turn alters insulin signaling and action (49). 
Lipodystrophic mice, such as the AZIP/F-1 mice, are also hypertensive (50). 
They have also been shown to have a high susceptibility to carcinogenesis that is 
thought to be related to their insulin resistance and inflammatory state (51) 
and/or the lack of adipose tissue (52).  
Treatment of Lipodystrophy in Mice: Leptin Replacement Therapy 
The metabolic abnormalities associated with lipoatrophy are clearly due to 
the lack of white adipose tissue since surgical implantation of adipose tissue 
reversed diabetes in lipoatrophic mice (53). Transplanting adipose tissue lacking 
leptin into AZIP/F1 fatless mice, however, could not reverse the phenotype of 
these mice. This evidence suggests that neither adiponectin deficiency nor the 
lack of triglyceride accumulation into fat per se is responsible for the metabolic 
abnormalities; it is rather leptin deficiency (54). Ebihara et al produced doubly 
transgenic mice that are lipodystrophic but over-express leptin. The mice showed 
hypophagia, improved insulin sensitivity and reduced hepatic steatosis in 
comparison with pair-fed lipodystrophic mice suggesting that leptin (rather than 
simply reduced food intake) exerted important metabolic benefits (55). In a study 
conducted by Shimomura et al, leptin administration to lipodystrophic mice via 
pumps achieving physiologic levels resulted in a noted improvement in 
hypertriglyceridemia, insulin resistance, hyperglycemia and hepatic steatosis 
(56). In another study, leptin reversed hyperglycemia and hyperinsulinemia in 
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Irs1-/-,Irs3-/- double knockout lipoatrophic mice (57). Furthermore, leptin infused 
centrally over 6 days to streptozotocin-induced diabetic rats (insulin-dependent 
diabetes) promoted euglycemia, an effect that was not due to regulating food 
intake or peripheral insulin levels, it was rather via regulating liver glucose 
production, energy expenditure and peripheral glucose uptake (58). Leptin 
replacement therapy also has other physiologic effects, beyond the control of 
food intake, hypertriglyceridemia, hyperglycemia and liver steatosis. For 
instance, Suganami et al found marked nephropathy in AZIP fatless mice which 
was reversed by leptin administration and prevented in the AZIP 
transgenic/Leptin transgenic mouse that is fatless but produces leptin (59). 
Vascular Function/Thrombosis  
A procoagulant state has been observed in obese patients with insulin 
resistance and in type 2 diabetes (60). In addition, inflammation resulting from 
obesity may play a role in the development of atherosclerosis (61). Plaque 
disruption in atherosclerosis triggers a thrombotic response characterized by the 
formation of a thrombus in the atherosclerotic blood vessel thus potentially 
exposing it to occlusive thrombosis and tissue (e.g. myocardial or cerebral) 
infarction (62). Acute thrombosis, therefore, often mediates the clinical severity of 
cardiovascular disease complications (63).  
Many circulating substances altered in metabolic disease are thought to 
influence thrombosis. Adiponectin, a protein produced by adipose cells, seems to 
be reduced with the increase in adipose stores (64). Thrombus formation is 
increased in adiponectin-deficient mice, a phenotype that was reversed when 
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introducing adiponectin via an adenovirus, suggesting that adiponectin plays an 
antithrombotic role (65). Acute high doses of TNF-α, the inflammatory mediator 
secreted by inflammatory cells (66), were also shown to have an antithrombotic 
effect in mice (67). PAI-1 has a detrimental effect on fibrinolysis being the 
primary inhibitor of tissue plasminogen activator in the blood (68) and it plays a 
prothrombotic role according to arterial thrombosis studies in mice (69). Another 
factor that has been shown to play a role in thrombosis is the adipose-derived 
hormone leptin. 
Leptin and Thrombosis 
Leptin appears to act as a prothrombotic factor. For example, leptin has 
been shown to stimulate platelet aggregation via adenosine diphosphate (70). 
The human platelet has a functional leptin receptor that was identified by 
Maruyama et al in 2000. High concentrations of leptin promoted platelet 
aggregation in vitro (71). Two human studies suggested that leptin is an 
independent risk factor for coronary heart disease (72). Also, plasma leptin levels 
were significantly associated with coronary artery calcification in a cross-
sectional study involving type 2 diabetes patients, after controlling for age, 
gender and other factors such as adiposity and CRP. This finding led to the 
suggestion that leptin may promote the proatherosclerotic risk posed by adiposity 
(73).  
Similar effects were also found in mice. Leptin, and especially exogenous 
leptin, was shown to be positively correlated with vascular thrombosis in various 
mouse models (30). Bodary et al found that daily leptin administration for 4 
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weeks promoted thrombosis and atherosclerosis in apolipoprotein E- deficient 
mice (74). The prothrombotic effect of leptin may be exerted via multiple sites 
including leptin receptors on platelets, centrally-mediated sympathetic effects of 
leptin (e.g. on blood pressure), as well as leptin receptor expression on 
endothelial cells (69).  
Consistent with the prothrombotic effect of leptin, the absence of leptin 
has been shown to reduce thrombus formation. For example, thrombosis is 
delayed and the thrombi formed are unstable in both leptin-deficient (ob/ob) and 
leptin receptor-deficient (db/db) mice. Leptin administration increased platelet 
aggregation thus enhancing the formation of and stabilizing thrombi in the former, 
but not in the latter, suggesting a receptor-dependent effect of leptin on platelet 
function and hemostasis (75). Mice with leptin receptor-deficient bone marrow 
were protected from photochemical injury-induced arterial thrombosis. Leptin 
administration has a prothrombotic effect following vascular injury in mice, an 
effect that was absent in leptin receptor-deficient mice and seemed to be driven 
by the interaction between leptin and the platelet leptin receptor (76). In addition, 
inhibiting endogenous circulating leptin delayed arterial and venous thrombosis in 
mice and rendered the formed thrombi unstable (77). 
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Chapter 2 
Objectives of this Study 
  Given the background information, the aims of this study were to 1) 
Observe the thrombotic profiles of FVB/B6 Lipodystrophic mice; 2) Observe the 
physiologic development and metabolic profiles of these mice via various 
parameters; and 3) Examine the effect of exogenous leptin on these profiles, 
while comparing to vehicle-treated and non-transgenic controls.  
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Chapter 3 
 
Materials and Methods 
 
Animals 
AZIP/F-1 transgenic (AZIP-TG) mice (strain name: FVB-Tg(Azip/F)1Vsn/J) 
were obtained from The Jackson Laboratory (Bar Harbor, ME) and bred in house 
to produce AZIP/F1 offspring. AZIP-TG mice express the AZIP/F1 gene under 
the control of 7.6 kB of the adipocyte specific Fabp4 promoter and therefore have 
nearly no white adipose tissue and a significantly reduced amount of brown 
adipose tissue (42). AZIP-TG females are infertile or weakly fertile due to the 
necessity of leptin and/or adipose tissue for lactation and fertility. Therefore, to 
obtain a mix of transgenic and wild-type FVB/B6 F1 offspring, several steps were 
followed: AZIP-WT females were crossed with AZIP-TG males. The offspring of 
interest were the AZIP-TG males. C57BL/6J (B6) female mice were purchased 
from Jackson Laboratories as well. The AZIP-TG males were crossed with B6 
females (at sexual maturity, i.e. ~6 weeks of age) to obtain FVB/B6 F1 offspring. 
B6 mice were chosen because they are the best characterized mouse strain for 
metabolic phenotypes and are genetically not close to the FVB strain (78). In 
addition, we had previously found FVB AZIP-TG mice to be sickly and poorly 
viable for use in our photochemical injury model of arterial thrombosis. The FVB 
x B6 offspring were found to be ideal for our studies as this breeding strategy had 
reduced mortality among the AZIP-TG offspring.  
The offspring of interest for the leptin pump study were the FVB/B6 males, 
both transgenic and wild-type. Males were chosen rather than females because 
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they are more biologically stable than the latter and do not encounter estrous 
cycling, providing more controlled conditions for the experiment. Mice were ear-
tagged and tailed (for genotyping purposes) and weaned at two and three weeks 
of age, respectively.  
       All laboratory personnel had completed the required animal-handling 
training offered by the Division of Laboratory Animal Resources (DLAR) under 
the supervision of Wayne State University’s Animal Investigation Committee 
(AIC) for proper handling of mice. The protocols used in the study were also 
approved by the AIC prior to the initiation of the study. All mice were housed in 
an animal room with ~53% relative humidity and a 22˚C ambient temperature.  
Feeding 
Breeders were fed the FormuLabDiet 5008 from LabDiet, which is a high-
energy high-protein formula used in breeding colonies of rodents to maximize 
reproduction. All other mice were fed Laboratory Rodent Diet 5001 from LabDiet, 
which is a constant formula used to diminish nutritional variables in long-term 
studies (PMI Nutrition International, Saint Louis, MO). All mice had access to 
food and water ad libitum. 
Genotyping  
Genotypes of mice were determined via end-point Polymerase Chain 
Reaction (PCR). Tail tip amputations were performed and DNA samples were 
obtained from tail sections. Tail sections were digested using a solution that is 
10% tail digestion buffer (50% 1M KCL, 20% 500mM Tris-HCL, 10% 10% Triton 
X-100, 20% ultra pure water), 4% 10mg/ml Proteinase K enzyme and 86% ultra 
15 
pure water. One hundred microliters of the solution was added to each tail 
sample and the samples were incubated at 55oC overnight, mixed using the 
Vortex Mixer (Fisher Scientific, Pittsburgh, PA) and spun at 16,100 x g for 10 
minutes at room temperature in the Eppendorf Centrifuge 5415 D (Brinkman 
Instruments, Westbury, NY). PCR reactions were performed using an Eppendorf 
Mastercycler Gradient PCR machine (Brinkman Instruments) and utilizing four 
“Azip” primers from Sigma-Genosys (Sigma-Aldrich, St. Louis, MO): Azip Mutant 
1981 (sequence 5'-CTGTGCTGCAGACCACCATGG), Azip Mutant 1982 r 
(sequence 5'-CCGCGAGGTCGTCCAGCCTCA), Azip Wild-Type 0042 
(sequence 5'-CTAGGCCACAGAATTGAAAGATCT) and Azip Wild-Type 0043 r 
(sequence 5'-GTAGGTGGAAATTCTAGCATCATCC), Go Taq Master Mix and 
Nuclease-Free Water (Promega, Madison, WI). Two and a half percent agarose 
gel was loaded with amplified product and Exactgene 100 BP DNA Ladder 
(Fisher Scientific) and run on a Fisher Biotech Electrophoresis System/ Wide 
Format Horizontal System FB-SB-2318 (Fisher Scientific). Gels were read via the 
DigiDoc-It Imaging System (UVP Inc., Upland, CA). 
Arterial Thrombosis 
  Blood flow was measured in 6 FVB/B6 (3 WT & 3 TG) male mice at 7-10 
weeks of age. The Arterial Thrombosis Protocol described by Bodary et al (76) 
was modified and followed: The procedure starts by anesthetizing the mice with 
~50 mg/Kg body weight intraperitoneal sodium pentobarbital (Meds for Vets, 
Sandy, UT) then securing them in the supine position and placing them under a 
dissecting microscope (Nikon SMZ-645, Mager Scientific Inc, Dexter, MI). A 
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midline cervical incision is then applied in order to isolate the right common 
carotid artery and apply a flow probe (model 0.5 PSB, Transonic Systems, 
Ithaca, NY). A flow meter (Transonic model T402, Transonic Systems) is then 
connected to the probe and blood flow is monitored via the computerized data 
acquisition software DASYLab9 (Measurement Computing Corporation, Norton, 
MA). The photochemical injury protocol described by Eitzman et al (79) was the 
means through which carotid arterial injury and thrombosis were induced. The 
photochemical used in this procedure is rose bengal (Fisher Scientific) which is 
diluted in PBS to 10 mg/mL and then injected into the tail vein via a 27-gauge 
Precision Guide needle with a 1-ml latex-free syringe (Becton Dickinson and Co, 
Franklin Lakes, NJ) at a dose of 50 mg/kg. Rose Bengal is then activated by 
exposing the mid common carotid artery to a 1.5-mW green light laser (540 nm, 
Melles Griot, Carlsbad, CA) from a 6 cm distance. Blood flow in the artery is 
observed from the time of the injection of rose bengal until the end of the 
experiment. Two events would determine the end point for the experiment: the 
cessation of blood flow in the carotid artery for one minute (read via the 
DASYLab9 software) and the visualization of an occlusive thrombus at the injury 
site via the dissecting microscope. The observer of both events would be blinded 
to the mouse group. 
Cell and Platelet Counts 
Blood cell and platelet counts were obtained from seven FVB/B6 F1 males 
(4 TG and 3 WT) at 13 weeks of age. Blood was obtained via a cardiac puncture 
terminal bleed using a 25-gauge Precision Guide needle with a 3-mL latex-free 
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syringe (Becton Dickinson and Co, Franklin Lakes, NJ) loaded with 3.2% Na-
Citrate (Sigma Inc., St. Louis, MO) where fresh circulating blood was obtained 
from the heart (ratio of Na-Citrate to Blood was 1:10) and diluted with PBS to a 
10,000 fold dilution. Ten microliters of diluted blood from each sample was 
placed in the Hausser Levy Hemacytometer (VWR International Inc, Batavia, IL) 
where platelets and total blood cells were counted under a Wilovert S Inverted 
Microscope (Hund Wetzlar, Germany).  
Euglobulin Clot Lysis Assay 
A Euglobulin Assay was performed on blood samples obtained from five of 
the mice (2 WT and 3 TG) mentioned above for the determination of fibrinolysis. 
The protocol described by Smith et al (80) was followed with modifications. The 
fresh citrated blood was spun and plasma was separated (described later) and 
mixed with working acetic acid (1.3 ml per 75 ul plasma) in 1.5-2.0 ml 
polypropylene tubes. The tubes were placed on ice for 10 minutes and spun at 
2,000xg for 5 minutes at room temperature. Supernatants were discarded and 
the tubes were inverted to drain for 5 minutes. The "euglobulin fraction" was 
resuspended in 100 ul of a solution of 154 mM NaCl and 26 mM sodium borate, 
stirred, warmed to 37oC for 90 seconds, re-stirred and warmed again to 37oC for 
90 seconds. Samples were then pipetted into a pre-warmed 37oC 96-well 
polystyrene flat-bottom microtiter plate, 90 ul per well. Each sample was pipetted 
in duplicate and read on the ELx800 Absorbance Microplate Reader at 405 nm. 
Ninety microliters of 0.025 M CaCl2 was added to one well of each sample while 
the other served as an individual control. The plate was placed again in the 
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microplate reader and absorbance was read at 405 nm every minute for the first 
10 minutes and then once every 10 minutes for 3 hours. Maximum absorbance 
was defined as the peak absorbance at 405 nm and lysis time was defined as the 
time at which the curve, corrected for the individual blank, reaches an 
absorbance of 0.05 or less.  
CBC and PT Measures 
Obtaining complete blood counts (CBC) and measuring clotting factors 
were also steps followed towards trying to uncover the mechanism behind the 
altered thrombotic profiles of AZIP-TG mice. Seven 28-week-old female FVB/B6 
F1 mice (3 WT & 4 TG) were sent to the Division of Laboratory Animal 
Resources (DLAR) clinical pathology lab (WSU) for CBC and measures of 
prothrombin time (PT) from fresh blood. Each mouse was placed in a CO2 
chamber for 30-45 seconds and blood was drawn via cardiac puncture. CBC 
measures were obtained via Heska CBC-Diff Veterinary Hematology System 
machine (Heska Corporation, Fort Collins, CO) and HeskaView Integrated 
Software Product Version 2.0.2 data acquisition software (Heska Corporation). 
PT was measured on the SCA2000 Veterinary Coagulation Analyzer 
(Symbiotics, San Diego, CA) using IDEXX Coagulation Diagnostics PT 
Cartridges (IDEXX Laboratories, Westbrook, ME). 
a-PTT Measures 
Seven female FVB/B6 F1 mice (4 TG, 3 WT) at 41-47 weeks of age were 
sent to the DLAR clinical pathology lab to obtain levels of activated partial 
thromboplastin time (a-PTT). The same bleeding protocol (as above) was 
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followed. The a-PTT was also measured on the SCA2000 Veterinary Coagulation 
Analyzer (Symbiotics) using IDEXX Coagulation Diagnostics a-PTT Cartridges 
(IDEXX Laboratories).  
Grouping for the Leptin Pump Study 
To study the effect of leptin administration on thrombotic and metabolic 
profiles of fatless mice, leptin was administered to the mice via osmotic pumps. 
Sixteen FVB/B6 mice were divided into four groups as follows: 4 transgenic mice 
that received leptin pumps (TG-Tx), 3 transgenic mice that received control 
pumps (TG-C), 4 wild-type mice that received leptin pumps (WT-Tx) and 5 wild-
type mice that received control pumps (WT-C). Reduced fertility in fatless mice 
along with the difficulty of obtaining healthy male offspring limited the sample size 
to 16 mice. 
Leptin Pumps  
Five µg leptin/day was administered to each mouse via an osmotic pump 
over 12 days. Recombinant mouse leptin was obtained from the National 
Hormone and Peptide Program (NHPP, Torrance, CA) and reconstituted with 
PBS pH 7.4 by GIBCO (Invitrogen, Grand Island, NY) into a 0.83 ug/ul 
concentration. ALZET Osmotic Pumps model 1002, Alza (DURECT Corporation, 
Cupertino, CA) were used to deliver leptin at a rate of ~0.25 ul/hr. Pumps were 
filled and primed following the company's instructions.  
Surgical Procedure for Pump Implantation 
The least invasive procedure, subcutaneous implantation, was used to 
implant leptin and vehicle pumps in the mice at 8 weeks of age, under sterile 
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conditions and following the company’s protocol. The mouse is first anesthetized 
with inhaled Attane Isoflourane, USP (MINRAD, Inc., Bethlehem, PA). The lower 
dorsal area is shaved, slightly posterior to the scapulae and a mid-scapular 
horizontal incision is made in the skin (≈ 1 cm). Using a hemostat or forceps, a 
pocket/path is created for the pump all the way along the spine, just before the 
neck. The filled pump is then inserted in the pocket. Finally, the incision is sealed 
with Oasis surgical adhesive (Oasis, Mettawa, IL) and the mouse is placed in a 
separate cage. The pump contents are delivered into the local subcutaneous 
space and absorbed by local capillaries resulting in systemic administration.  
 (Procedure modified from: Alzet technical Information manual, Durect 
Corporation, Cupertino, CA). 
Blood Samples 
Blood samples were obtained from mice one week prior to inserting 
pumps, i.e. at ~7 weeks of age, via retro-orbital bleeds (orbital sinus 
venipuncture), using Fisherbrand heparinized micro-hematocrit capillary tubes 
cat # 22-362-566 (Fisher Scientific). Two bleeds were done at 7 weeks of age (2-
3 days apart), so that adequate amounts of both plasma and serum could be 
isolated to measure pre-pump parameters. On the 9th day of having the pump in, 
during their 9th week of age, the mice were bled again for serum samples, to 
measure effects of leptin treatment. All blood samples were obtained after a five-
hour fast where the mice would have access to water only. For plasma samples, 
blood was collected in 1.5 ml polypropylene tubes, spun immediately (or kept at 
4oC until spinning) at 5,000 x g for 10 minutes at room temperature and plasma 
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was isolated and stored at -20oC. For serum samples, blood was collected in BD 
Microtainer Serum Separators Ref 365959 (Becton Dickinson and Co), clotted for 
two hours at room temperature, spun at 2,000 x g for 20 minutes at room 
temperature and serum was isolated and stored at -20oC. These bleeding and 
plasma/serum isolation procedures were followed in all other experiments 
requiring blood samples, unless otherwise indicated.  
Measuring Blood Glucose 
On day 9 after pump placement, while bleeding for serum samples, fasting 
blood glucose concentrations (mg/dl) were measured using the Ascensia Elite XL 
glucometer (Bayer, Tarrytown, NY), to monitor differences between groups. 
Monitoring Body Weight Change 
During leptin pump experiments, parameters that were to be measured 
daily were body weight and food intake. The mice were weighed at 10:00 am 
everyday throughout the study using the Adventurer-Pro digital scale (Ohaus 
Corporation, Pine Brook, NJ), to monitor weight change in response to leptin 
treatment. Food remaining in the cage was weighed daily during the first week of 
the experiment and food intake was estimated by subtraction. However, the 
measurement was discontinued because food was being chewed but not 
consumed, making the results very inaccurate. 
Arterial Thrombosis (leptin pump study) 
Blood flow was monitored on the twelfth day following pump placement, at 
10 weeks of age, following the protocol previously described. The maximum 
duration allowed for observing blood flow was 150 minutes in the FVB/B6 leptin 
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pump experiment. Again, the observer was blinded to the mouse group 
(treatment vs control, transgenic vs wild-type). 
Tissue Harvesting 
The above arterial thrombosis procedure is a non-survival protocol. After 
disconnecting the mice from the flow probe, while they were still under the effect 
of anesthesia, they were euthanized via a cardiac puncture terminal bleed for 
plasma isolation and they were then dissected to harvest organs. The liver was 
the primary organ of interest. Tissues were weighed while fresh and sections 
were consistently removed and frozen. Kidneys, hearts, lungs, spleens and fat 
pads (in WT mice) were also isolated and weighed. All isolated tissue/organ 
samples were weighed using the Mettler Toledo digital scale Model XS104 
(Mettler-Toledo, Columbus, OH) and stored in 1.5-2 ml tubes at -20oC. Blood 
obtained from the terminal bleed was spun for plasma isolation, following the 
same isolation technique used in previous bleeds. 
Liver Homogenization  
Frozen liver tissue was thawed and homogenized in order to be used in 
assays to measure parameters of interest. Fifty milligrams of each liver sample 
was homogenized in a BD Falcon Polypropylene Round Bottom Tube (Becton 
Dickinson and Co) in 2 ml of lysis buffer (150 mM NaCl, 0.1% Triton X-100, 10 
mM Tris) using a Model Pro200 Double-Insulated Homogenizer (PRO Scientific, 
Oxford, CT). The resulting 5-fold diluted livers were spun and supernatants were 
used in assorted assays as described. 
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Measuring Leptin Levels 
Leptin levels were measured in serum samples of mice pre and post pump 
treatment, via a leptin ELISA. The Mouse Leptin ELISA Kit Catalog # 90030 
(Crystal Chem, Downers Grove, IL) was used with provided standards and 
controls. 
Measuring Insulin Levels 
To test the effect of leptin administration on insulin sensitivity in our 
samples, serum insulin levels were measured by ELISA as well. The Ultra 
Sensitive Mouse Insulin ELISA Kit Catalog # 90080 (Crystal Chem) was utilized 
with the provided wide range standards. 
Measuring Triglyceride Levels 
Plasma and liver triglyceride levels were measured using the Serum 
Triglyceride Determination Kit Catalog # TR0100 (Sigma-Aldrich, Saint Louis, 
MO) with provided reagents. Liver triglyceride concentrations were then 
normalized for liver protein concentrations. Liver samples used in the assay were 
diluted 40-fold with deionized water. 
Measuring Cholesterol Levels  
Plasma and liver cholesterol levels were measured using a cholesterol 
assay following the Wako Cholesterol E Microtiter Procedure Catalog # 439-
17501 (Wako Diagnostics, Richmond, VA). Liver cholesterol concentrations were 
also normalized to liver protein concentrations. Livers samples used were diluted 
five-fold with deionized water.  
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Measuring Liver Protein Concentration 
Liver protein concentration was measured using Bio-Rad RD DC Protein 
Assay dye reagent (Bio-Rad, Hercules, CA) and bovine serum albumin 
standards. Absorbance was read at 570 nm. Livers were 2000x diluted for this 
purpose. 
All assays were read using the ELx800 Absorbance Microplate Reader 
(Bio-Tek Instruments, Winooski, VT) and the KC4 Software (Bio-Tek). 
Statistical Analyses 
Results were analyzed via SPSS 15.0 for Windows (SPSS Inc., Chicago, 
IL) using one way Analysis of Variance (ANOVA), two way ANOVA, paired 
samples t-test and independent samples t-test. Post-hoc analyses were also 
used to compare outcomes using p≤0.05 as a cutoff point for statistical 
significance (significant effect). Due to the limited mice available for these 
analyses (and the high risk of a type 2 statistical error), a p≤0.1 is noted to 
identify comparisons that should be examined more closely in the future. Mean 
and standard error of the mean were calculated for each dependent variable. 
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Chapter 4 
Results 
A- Prior to Leptin Pump Study   
Preliminary Thrombosis Data 
   Our thrombosis trial reveals a tendency of lipodystrophic mice to have a 
delayed clotting in response to photochemical arterial injury. When compared to 
WT littermates, TG mice had significantly longer time to arterial occlusion 
(p<0.05) revealing delayed formation of a thrombus (Figure 1). This observation 
prompted us to conduct several investigations. 
Hematology 
   Aiming towards finding factors responsible for the altered thrombotic 
profile observed in fatless mice, blood cell and platelet counts were obtained 
from TG mice and WT controls. The small differences observed were not 
statistically significant: blood cell counts (x 109/L) were 8.95 + 0.34 and 8.03 + 
0.21 in TG and WT mice, respectively. Platelet counts (x 109/L) were 1.93 + 0.13 
in TG mice and 1.53 + 0.21 in WT mice. 
   Also within the search for underlying factors behind delayed clotting in 
fatless mice, a Euglobulin Assay was performed on blood samples obtained from 
the same mice mentioned above for the determination of plasma fibrinolytic 
activity. As shown in Figure 2, the TG and WT mice had similar trends and 
therefore no significant differences in fibrinolysis. 
   Furthermore, PT and a-PTT were measured in lipodystrophic mice and 
wild-type controls and also, no significant differences were observed. PT (sec) 
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was 21.75 + 0.63 in the TG group and 20 + 1.53 in the WT group. a-PTT (sec) 
was 59.5 + 9.56 and 59.66 + 1.45 in TG and WT mice, respectively.  
   CBC measures were obtained from TG mice and WT littermates and no 
significant differences were found between the two groups, as shown in Table 1.  
   The above findings, therefore, reveal no significant differences between 
WT and TG mice in hematologic and fibrinolytic factors that might explain the 
unexpected anti-thrombotic trend of the AZIP-TG mice. We thus proceeded to 
leptin administration. 
B- Leptin Pump Study 
Arterial Thrombosis 
   The arterial thrombosis data are tabulated in Table 2. A major 
complication was encountered during the arterial thrombosis protocol: death of 4 
TG mice before occlusion (> 50% of the TG mice). The TG Tx mice that survived 
(2 mice), however, did not have the faster clotting that was hypothesized. An 
occlusive thrombus was not formed and the experiment was discontinued at 150 
minutes. The same non-clotting phenotype was observed in the only TG C 
mouse that survived, consistent with the preliminary data of the TG mice. The TG 
group had a significantly prolonged time to clotting when compared to the WT 
group (p<0.05), as demonstrated in Figure 3. As for WT mice, the difference in 
clotting time between the treated and the untreated groups was not significant.  
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Body Weights 
   At baseline, TG mice were significantly heavier than their WT littermates 
(p=0.01). Leptin treatment significantly reduced the body weight of both the TG 
mice (p<0.005) and the WT mice (p<0.05) (Figure 4).  
   Figure 5 depicts the percent body weight change in response to 
treatment. The values obtained reveal a significant difference in the changes in 
body weight between the TG C and the TG Tx groups (p=0.001).  
Blood Parameters 
   Baseline leptin differences between WT mice and TG mice were huge. 
WT mice had remarkably higher levels, as leptin levels in TG mice were nearly 
undetectable. Figure 6 shows that serum leptin concentration increased with 
treatment in both the TG mice (p<0.01) and the WT mice (p<0.05). Control TG 
mice had no change in leptin concentration. 
   Even though the leptin-treated TG mice had lower blood glucose 
concentration (88.5 + 30.1) compared to the vehicle-treated TG mice (139.6 + 
42.5), this difference (p=0.1) did not reach statistical significance. Values for WT 
mice were also not significantly different (C: 126.4 + 6.9; Tx: 106.8 + 7.5).  
   Figure 7 refers to the change in serum insulin concentration observed in 
the WT and TG groups. At baseline, the TG mice had remarkably higher insulin 
concentration than the WT mice (p=0.001), as expected. The treatment of TG 
mice with leptin resulted in a significant reduction in insulin concentration 
(p<0.05). The same effect was seen in the WT mice. No significant changes were 
observed in control mice.   
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   Homeostasis Model Assessment for estimated insulin resistance (81), 
HOMA-IR, was computed to analyze the difference in insulin resistance between 
the groups. HOMA-IR scores revealed a significantly higher insulin resistance in 
the TG C group when compared to the TG Tx group (p=0.01) and either of the 
WT groups (p=0.005), as follows: TG C 131.2 + 65.9 > TG Tx 17.4 + 15.1 = WT 
C 6.65 + 2.15 = WT Tx 3.39 + 1.68. 
   Prior to treatment, TG mice had significantly higher levels of triglyceride 
in their plasma when compared to WT mice (p=0.005). Plasma triglyceride 
concentration did not change significantly after treating the mice with leptin, in 
either the TG or WT mice, as shown in Figure 8. However, there was an 
unexpected increase in triglyceride in the WT control group.  
   Plasma cholesterol concentration, as Figure 9 reveals, significantly 
dropped in the TG mice upon treatment with leptin (p<0.05). In addition, both the 
treatment and control WT mice had a reduction in plasma cholesterol (p<0.05). 
The vehicle-treated TG mice did not encounter any significant changes. 
Liver Parameters 
    Protein concentration in livers of the mice was computed for the purpose 
of normalizing liver parameters to protein levels.  
   The liver triglyceride to protein ratio, shown in Figure 10, reveals a 
significant difference in triglyceride concentrations between the control TG mice 
and the control WT mice (p<0.05), with the former being higher as expected for 
“fatless mice”.  A trend was evident (p=0.089) for the leptin-treated TG mice to 
have a lower liver triglyceride to protein ratio than the vehicle-treated TG mice.
29 
   No significant differences were observed in liver cholesterol to protein 
ratios (mg:mg) between groups (TG C 0.0046 + 0.0016 = TG Tx 0.0031 + 0.001 
= WT C 0.0041 + 0.001 = WT Tx 0.0042 + 0.001). 
Harvested Organ and Tissue Weights 
   Weights of livers of the mice involved in the study are displayed in 
Figure 11 which shows that leptin-treated TG mice had significantly smaller 
livers than vehicle-treated TG mice (p<0.05). Moreover, TG-C mice had 
significantly larger livers than WT-C mice did (p<0.0001). Livers of the leptin-
treated TG mice were still significantly heavier than either of those of the WT 
mouse groups (p<0.01) i.e. the control WT mice and the treated WT mice. The 
differences observed were significantly affected by both the genotypes of the 
mice (p<0.0001) and the treatment they received (p<0.05).  
   Results for the other organs that were weighed are shown in Figure 12: 
Organ weights were significantly affected by genotype. However, the difference 
in these weights between the control TG mice and the treated TG mice was not 
significant. TG mice had heavier spleens, hearts and kidneys than WT mice 
(p<0.05), consistent with previous observations. Neither genotype nor treatment 
showed a significant effect on differences in lung weights. 
   Figure 13 graphs the fat pad weights obtained from the mice. Upon 
dissection, fat pads from different areas of the mouse body were acquired, i.e. 
dorsal, perirenal and gonadal fat. The weight obtained is a combination of all the 
above mentioned fat pads weighed together. No visible adipose tissue was found 
in the TG mice, whether treated or untreated. The leptin-treated WT mice had 
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significantly less fat following the intervention than their control littermates 
(p=0.005).  
   Figure 14 displays two livers, one obtained from a TG mouse and 
another obtained from a WT mouse. The evident difference lies mostly in the size 
of the liver where that of the TG mouse is radically larger than that of the WT 
mouse (hepatomegaly). A difference in the liver color can also clearly be seen 
with the fatty TG mouse liver having a lighter color (due to increased fat 
deposition). 
   Figure 15 shows a dorsal view of 2 skinned mice: a TG and a WT.  
Hepatomegaly which is a characteristic property of lipodystrophic mice is evident 
in this TG mouse, in addition to the absence of fat pads. The WT mouse, on the 
contrary, has a normal dorsal appearance. 
 
31 
Chapter 5 
Discussion 
Significant Findings Prior to the Leptin Pump Study 
  The absence of adipose tissue results in several detrimental effects on 
the metabolic and physiological profiles of patients with lipodystrophy, most of 
which have been explored. However, even though “better” treatments exist, the 
“ideal” or “ultimate” treatment is yet to be found (5-12). Moreover, the 
mechanisms underlying the observed alterations need to be more clearly 
understood, which may be a key to advancing treatment options. The AZIP/F-1 
mouse model, as mentioned previously, shares many characteristics with 
lipodystrophic patients and therefore provides an animal model of severe 
lipodystrophy on which studies can be performed to unlock the mysteries of this 
disease and assist in finding better treatment options (1, 42). It is a mouse model 
with a complex phenotype. The metabolic aspects of this phenotype have been 
fairly well studied; however, we were curious about other aspects, such as 
thrombotic function.  
  Our arterial thrombosis trial revealed a remarkable and surprising 
phenotype in the fatless mice: prolonged time to arterial occlusion/clotting when 
exposed to photochemical arterial injury, compared to wild-type littermate mice. 
Impaired vascular function has been previously seen in these mice though in a 
different way. According to Takemori et al, A-ZIP/F1 lipoatrophic mice are 
hypertensive, likely secondary to the lack of perivascular fat tissue and an 
upregulation of vascular Ang II type 1 receptors (82). Lamounier-Zepter et al later 
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suggested that the high blood pressure observed in these mice may be due to 
metabolic-vascular alterations including changes in adrenocortical cells and the 
hypercorticosteronemia seen in the mice (83). Thrombosis, however, has not 
been examined in these mice. The fatless mice phenotype described above, 
therefore, prompted us to investigate about the etiology through examining blood 
counts and clotting factors in these mice compared to WT controls. We first 
started with the blood cell and platelet counts that were not significantly different 
between the TG and WT mice. This meant that there must be a factor beyond 
cell and platelet counts that may still be related to blood/thrombotic profiles of the 
mice. The next step was determining fibrinolysis that we thought might be altered 
in the transgenic mice. However, the euglobulin clot lysis assay that we 
performed resulted in similar fibrinolysis trends between the TG and the WT 
mice, although the baseline absorbance was different between the groups. We 
rendered that to the turbidity that we observed in the plasma samples of the TG 
mice, which in turn can be explained by the previously demonstrated 
hyperlipidemia in the blood of these mice (42, 44, 45). We then proceeded to 
obtaining CBC’s and PT tests from TG mice and WT controls where again, 
differences between the two groups were not evident. Our last step in evaluating 
hematologic and fibrinolytic differences was measuring a-PTT which also was not 
different in the TG mice when compared to their WT littermates. Our conclusion 
was that the delayed clotting observed in these mice must be the result of a 
mechanism or an anomaly that is not related to hematologic and fibrinolytic 
factors but rather to a different characteristic of lipodystrophic mice. 
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Arterial thrombosis trials performed in the past have shown a positive 
correlation between leptin and blood clotting, i.e. in other words, leptin has been 
shown to promote platelet aggregation and therefore blood clotting in humans 
(70, 71) as well as in mice (74-77). Leptin is very low or undetectable in AZIP-TG 
mice (42) and at the same time our mice had normal blood counts and clotting 
factor profiles as previously stated. These findings combined led to the 
hypothesis that the absence of leptin may be behind the altered thrombotic 
phenotype seen in our lipodystrophic mice. By providing these mice with leptin, 
we could test the above hypothesis and examine the metabolic effects of leptin 
administration specifically on the FVB/B6 lipodystrophic mice. We therefore 
provided our four mouse groups with leptin or control solutions exogenously and 
compared the parameters and changes of interest at different time intervals. 
Arterial Thrombosis  
 Although we had a minimal number of successful thrombotic 
experiments to rigorously test our hypothesis, our data do not support an effect of 
leptin on thrombosis in the A-ZIP mice. Regardless of whether or not they were 
receiving leptin, we observed an extremely delayed occlusion time after 
photochemical injury to the carotid artery of A-ZIP TG mice. We have not been 
able to attribute this surprising alteration to enhanced fibrinolysis, deficient 
clotting factors, or abnormal blood/platelet counts. Although we regret that we 
were unable to obtain an adequate number of animals to carefully test our 
hypothesis, we feel relatively confident that leptin does not “rescue” the altered 
thrombotic phenotype of the A-ZIP mice. Our poor success in attaining the 
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arterial thrombosis endpoint in these studies (with mortality of more than half of 
our TG mice during the procedure), is a function of the difficulty in delivering 
anesthesia to these mice. Maintaining their depth of anesthesia at an adequate 
level (without overdose) is very difficult, as previously mentioned in studies of the 
AZIP-TG mouse (42). 
Body and Organ/Tissue Weights 
  TG mice weighing more than WT mice was not surprising. This was seen 
previously (42) and can be explained by organ enlargement that fatless mice 
encounter as they mature, especially hepatomegaly (42, 44, 45). As expected, 
treatment with leptin led to a decrease in body weight in both the TG and WT 
mice. This finding is not surprising since leptin is known to control weight via 
controlling energy intake and metabolism (15, 16). The reduction in body weight 
may further be attributed to increasing energy expenditure in the WT mice though 
this may be unlikely in the TG mice since leptin therapy has been associated with 
a reduction in energy expenditure in lipodystrophic subjects (5, 10). 
  The trends of organ and tissue weights were also as we had expected. 
Livers of TG mice were significantly larger than those of WT mice, which has 
been previously shown (42, 44, 45). This difference in size is attributed to several 
factors, mainly the fact that the liver in lipodystrophic animals is acting as a 
storage depot that also stores what would normally be stored in adipose cells, i.e. 
triglycerides (42), which leads to the previously proven hepatic steatosis in 
lipodystrophic mice (34-37, 42, 84). Moreover, the inflammatory state that is seen 
in these animals (51) may be playing a role in contributing to organomegaly, 
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mainly hepatomegaly, knowing that hepatic steatosis and inflammation have 
generally been shown to be associated (84). The livers of leptin-treated TG mice, 
on the other hand, were significantly smaller than those of the control TG mice, a 
result that was also predictable and supported by the literature (42, 44, 45). 
Leptin administration clearly ameliorated the hepatomegaly through enhancing 
metabolism. It attenuated the steatotic state, an effect that has been seen in both 
lipodystrophic patients (11) and mice (56). This may partly explain the described 
alterations in body weight observed in our TG mice. 
  Spleens, hearts and kidneys were heavier in TG mice than in WT mice. 
This is consistent with previous findings that reported organomegaly in 
lipodystrophic mice (42, 44, 45). These organs were not lighter in leptin-treated 
TG mice when compared to vehicle-treated TG mice. This may imply that some 
of the anomalies caused by lipodystrophy are irreversible. 
  The most exciting part of the dissections was the extensive search for fat 
pads. None were found in the TG mice. This coincides with previous findings (42, 
49) and explains most of the physiological and metabolic abnormalities. 
Importantly, leptin-treated WT mice had less fat than control WT mice did. This 
implies that leptin treatment was effective and that these WT mice were “leptin 
sensitive”. 
Blood and Liver Parameters 
At baseline, TG mice had very low levels of leptin (< 0.5 ng/ml), i.e. below 
normal physiological levels (85). This was anticipated due to the lack of fat in TG 
mice and therefore a lack of this adipocyte-derived hormone. Consistent with 
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this, serum leptin concentration has been observed to be directly proportional to 
fat mass (5). As expected, the WT mice had significantly higher leptin 
concentrations at baseline, which were in the normal physiologic range. Upon 
treatment, serum leptin levels in the leptin-treated TG mice increased robustly 
(almost 7-fold), while vehicle-treated TG littermates encountered no change in 
leptin concentration. These findings demonstrate that our leptin treatment (via 
osmotic pump) of TG mice effectively increased the serum leptin concentration 
into a normal physiologic range.  
Blood glucose (BG) levels of untreated TG mice were higher than those of 
treated mice where the former met the criteria for hyperglycemia and the latter 
fell within the normoglycemia range; however, these differences were not 
significant. This is likely due to the variability of the measure, the limited number 
of mice, and the modest elevation of glucose in this relatively young cohort. In 
future studies, it will be helpful to obtain BG levels at several time points to more 
accurately observe the effect of treatment on the mice. This was not done in this 
study in order to avoid excessive blood withdrawal from the mice and therefore 
additional stress.  
  TG mice, which were expected to be diabetic/ insulin resistant at the time 
of the blood draw, did have significantly more circulating insulin than did their WT 
controls, at baseline. In addition, compared to the TG control-treated mice (which 
became worse during the intervention period), the TG leptin-treated mice had 
significantly reduced fasting insulin concentration. This is consistent with 
previous findings where insulin resistance became progressively worse from 4 
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weeks of age to 10 weeks of age in the Azip fatless mice (49), and where leptin 
enhanced insulin sensitivity in fatless mice (55-57). We also observed a 
reduction in insulin concentration in leptin-treated WT mice suggesting that a 
deficit of leptin at baseline was not required for a decrease in fasting insulin 
during leptin treatment. 
  HOMA-IR scores confirmed that the TG C group was extremely insulin 
resistant and that this effect was ameliorated following leptin treatment. This is 
also consistent with the known insulin resistant phenotype of lipodystrophic mice 
(44, 45) that is improved with leptin therapy (56). 
  High circulating levels of lipids in the blood are expected in fatless mice 
that lack the normal mammalian fat storage depot (42). This was confirmed in our 
study when comparing these mice to controls at baseline. Triglyceride levels 
obtained from plasma samples did not change significantly in the TG mice. They 
seemed to remain almost the same upon treatment, which might imply that 
treatment at least prevented further increase in triglyceride concentration in the 
blood. The only significant change that was seen is an increase in triglyceride 
levels in the untreated WT mice. This may be a normal trend related to age. As 
for liver triglyceride measures, as expected, levels were higher in TG mice than 
in WT mice (vehicle-treated). This has been previously documented (49) as 
AZIP-TG mice are known to develop hepatic steatosis (42). Moreover, the leptin-
treated TG group had lower levels than did the vehicle group, which is supported 
by previous studies both in humans (5, 9) and in mice (56). These results are 
explained by 1) the fact that the liver in the TG mice acts as the major triglyceride 
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storage depot in the absence of adipose cells, causing triglyceride accumulation 
and hepatic steatosis; and 2) the fact that leptin improves triglyceride metabolism 
and thereby reduces hepatic triglyceride accumulation. 
  In both plasma and liver, there were no significant differences in 
cholesterol levels of TG versus WT mice. This was surprising as previous studies 
have reported hyperlipidemia in lipodystrophic mice (42, 44, 45). What was 
expected, however, is the reduction in plasma cholesterol concentration in the 
leptin-treated TG mice. This coincides with previous suggestions that leptin 
improves lipid metabolism in both lipodystrophic humans (11, 12, 86) and mice 
(55, 56). 
  Of interest, the A-ZIP phenotype has been demonstrated to be affected 
by genetic background. For example, A-ZIP mice on the FVB background have 
higher circulating triglyceride and fatty acid levels and more hyperglycemia than 
those on the B6 background according to Colombo et al in 2003 (43). This may 
explain some of the unexpected findings listed above. 
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Chapter 6 
Conclusion 
  The United States has been facing a remarkable increase in obesity over 
the last two decades, associated with several disorders (87-92). Nonalcoholic 
fatty liver disease is rapidly spreading mainly in the form of hepatic steatosis 
which in turn is a known component of obesity and the metabolic syndrome along 
with insulin resistance and hyperlipidemia (93). Insulin resistance and 
dyslipidemia can be caused by either excessive adiposity or lack of adipose 
tissue (94). Lipodystrophy, therefore, carries many of the same characteristics as 
more common metabolic diseases. This disease is being actively researched and 
effective mouse models have been produced, with the Azip-transgenic model 
being very similar in physiology and metabolism to some lipodystrophic patients 
(1, 42). Ongoing and future studies using these models should help explore the 
vague aspects of lipodystrophy and provide more effective treatment options for 
lipodystrophic patients.  
Adipose tissue serves as an endocrine organ through secreting several 
bioactive compounds (adipokines) whose dysregulation is thought to contribute 
to insulin resistance and metabolic disease (94). Leptin, a major adipokine, has 
an essential role in energy homeostasis (5). Low leptin levels appear to be a 
characteristic abnormality in lipodystrophic patients that can serve as an effective 
therapy for reducing their metabolic disease.  However, as previously introduced, 
there are many forms of lipodystrophy, so a clear mechanistic understanding of 
each disease will lead to the most effective treatment strategies.  
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In addition, the administration of adipokines other than leptin might be a 
promising future research option since these adipokines may turn out to be key 
players in many of the metabolic and physiological aspects of lipodystrophy, 
obesity and/or the metabolic syndrome. 
Aside from the metabolic and physiological characteristics, the transgene 
possessed by the fatless mice may be leading to an altered thrombotic function 
via mechanisms that are unrelated to the lipodystrophy or metabolic disturbances 
of this model. Therefore, adipose tissue transplantation in the A-ZIP 
lipodystrophic mice may help determine whether it is truly the absence of adipose 
tissue that induces the observed thrombotic alterations or whether the effect is a 
by-product of the transgenic strategy. Additionally, transplanting adipose tissue 
that lacks leptin may further aid in understanding and dissociating these factors. 
In the future, in a study like ours, a larger sample size and a longer 
duration would likely produce more significant outcomes with a reduced 
variability. These study-design improvements combined with the above research 
suggestions may help solve unanswered questions about the lipodystrophies and 
possibly find treatment targets not only for these disorders, but also for other 
chronic metabolic conditions such as diabetes. 
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Figure 1 
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Figure 1- Formation of Occlusive Thrombus in Wild-type (WT) and 
Transgenic Fatless (TG) FVB/B6 Mice. TG mice have a delayed time 
to arterial occlusion, compared to WT mice. 
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Figure 2 
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Figure 2- Euglobulin Clot Formation and Lysis in FVB/B6 Mice. 
Similar trends in fibrinolysis are observed in TG and WT mice.  
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Figure 3 
 
 
  
TG C TG Tx WT C WT Tx
0
30
60
90
120
150
180
Ti
m
e
 
to
 
O
cc
lu
si
o
n
 
(m
in
)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bars with different superscripts are significantly different from each 
other (p <0.05) 
 
Figure 3- Time to Formation of Occlusive Thrombus per Group. TG 
mice have a prolonged time to arterial occlusion, compared to WT mice. 
When comparing TG mice that survived, TG C (n=1) and TG Tx (n=2) 
are not different. 
 
a 
b 
b 
44 
Figure 4 
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Figure 4- Day by Day Body Weights per Group. TG mice are 
heavier than WT mice at baseline. Following the intervention, both TG 
and WT leptin-treated mice lost weight, comparing pre-treatment to 
post-treatment weights.  
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Figure 5 
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Figure 5- Percent Body Weight Change per Group. TG C mice 
continued to gain weight as they mature while leptin-treated mice (TG 
and WT) lost weight. 
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Figure 6 
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Figure 6- Change in Mean Serum [Leptin] per Group. Baseline 
serum leptin levels are higher in WT mice where TG mice have nearly 
undetectable levels. Both the TG and the WT leptin-treated groups 
had an increase in circulating leptin. 
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Figure 7 
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Figure 7- Change in Mean Serum [Insulin] per Group. Baseline 
serum insulin levels are higher in TG mice compared to WT mice. 
Both the TG and the WT leptin-treated groups had a reduction in 
insulin levels. 
48 
Figure 8 
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Figure 8- Change in Mean Plasma [Triglyceride] per Group. 
Baseline plasma triglyceride levels are higher in TG mice compared to 
WT mice. No significant reductions were observed upon treatment 
with leptin.   
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Figure 9 
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Figure 9- Change in Mean Plasma [Cholesterol] per Group. 
A significant reduction was observed in all groups except in the 
TG C group.    
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Figure 10 
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Figure 10- Mean Liver [Triglyceride:Protein] per Group. TG C 
mice have higher levels of liver triglyceride than WT C mice.  
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Figure 11 
 
 
 
  
TG C TG Tx WT C WT Tx
0
2
4
6
8
10
Li
v
e
r 
W
t a
s
 
%
 
TB
W
t  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bars with different superscripts are significantly different from each other 
(p <0.05) 
 
Figure 11- Mean Liver Weight as % Total Body Weight per Group. 
Livers of TG mice are heavier than those of WT mice. Livers of leptin-
treated TG mice are lighter than those of vehicle-treated TG mice. 
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Figure 12 
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Figure 12- Mean Organ/Tissue Weights as % Total Body 
Weight per Group. TG mice have larger organs compared to 
WT mice. No significant effect of treatment is seen. 
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Figure 13 
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Figure 13- Total Adipose Tissue Weight as % Total Body Weight per 
Group. Both groups of TG mice lack visible adipose tissue. WT Tx mice 
have less fat than WT C mice. 
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Figure 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 14- Mouse Livers Following Dissection. A TG mouse liver 
with hepatomegaly and steatosis (left) vs a healthy WT littermate liver 
(right). 
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Figure 15 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
Figure 15- Dorsal View of Skinned Mice with Intact Organs and 
Tissues. (a) The TG mouse has a large liver occupying most of the 
abdominal cavity and lacks visible fat pads. (b) The WT mouse has a 
normal dorsal view with the absence of organomegaly and the 
presence of fat pads. 
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Table 1: Complete Blood Counts (CBC) in Wild-Type Vs 
Transgenic FVB/B6 Mice (Mean ±SEM)   
 
Blood Parameter Genotype 
  Wild-type Transgenic 
Plt (103/ul) 492.33 + 65.9 567.25 + 55.1 
WBC (103/ul) 4.87 +  0.67 4.825 + 0.85 
RBC (106/ul) 9.77 + 0.44 9.70 + 0.66 
MCV (fl) 43.93 + 0.88 46.08 + 0.27 
RDW  18.67 + 0.59 17.9 + 0.34 
MCHC (g/dl) 35.2 + 0.75 34.78 + 0.28 
MCH (pg) 15.4 + 0.10 16 + 0.04 
MPV (fl) 6.33 + 0.07 6.4 + 0.04 
HGB (g/dl) 15.07 + 0.73 15.53 + 1.08 
% HCT 42.97 + 2.63 44.73 + 3.24 
% Lym 81.33 + 3.37 78.35 + 2.29 
% Mon 6.4 + 1.07 6.6 + 0.31 
% Gra 12.27 + 2.44 15.05 + 1.99 
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Table 2:  Leptin Pump Thrombosis Data: Time to Occlusion 
Mouse Group Time to Occlusion (m) Status 
TG C 48 Expired 
TG C 150+ Discontinued 
TG C 60 Expired 
TG Tx 150+ Discontinued 
TG Tx 87 Expired 
TG Tx 150+ Discontinued 
TG Tx 19 Expired 
WT C 53 Completed 
WT C 17 Completed 
WT C 47 Completed 
WT C 52 Completed 
WT C 80 Completed 
WT Tx 29 Completed 
WT Tx 31 Completed 
WT Tx 46 Completed 
WT Tx 59 Completed 
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ABSTRACT 
EFFECT OF EXOGENOUS LEPTIN ON THROMBOTIC AND  
  METABOLIC PROFILES OF FVB/B6 LIPODYSTROPHIC MICE 
by 
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May 2010 
Advisor: Dr. Peter F. Bodary 
Major: Nutrition and Food Science 
Degree: Master of Science 
Lipodystrophy caused by fat deficiency contributes to metabolic disease 
for which several treatment modalities have been implemented, with leptin 
therapy being the most effective to date. In addition to playing a role in energy 
homeostasis and metabolism, leptin was also shown to play a pro-thrombotic role 
in mice. This role was not examined in fatless mice, neither was thrombosis 
measured. The AZIP/F-1 (FVB) lipodystrophic mouse appeared to have a 
prolonged arterial occlusion time (p<0.05) in a trial done in our lab, with clotting 
factors being normal. The present study was designed to observe the thrombotic 
and metabolic characteristics of fatless mice and examine the effect of leptin 
therapy on these traits. 16 FVB/B6 mice were produced in-house for the study, to 
receive recombinant mouse leptin or saline via osmotic pumps over 12 days. 
Transgenic (TG) mice were randomly divided into two groups: Treatment (Tx, 
n=4) and control (C, n=3); and their wild-type (WT) littermates were similarly 
73 
divided into Tx (n=4) and C (n=5). TG mice had a prolonged time to formation of 
occlusive thrombus compared to WT mice (p<0.05). Leptin treatment did not 
have an effect on arterial thrombosis in our mice. At baseline/control, TG mice 
were heavier than WT mice (p<0.05), had larger livers (p<0.0001), larger kidneys 
(p=0.01), higher serum insulin (p<0.01), higher plasma and liver triglyceride 
(p<0.01 and p<0.05, respectively) and less leptin (p<0.0001). TG-Tx mice 
decreased in weight (p<0.05) and had smaller livers than those of TG-C mice 
(p<0.05) while having higher levels of circulating leptin (p=0.01) and reduced 
levels of serum insulin (p<0.05) and plasma cholesterol (p<0.05). TG C mice had 
higher HOMA-IR scores (p<0.05) than all other groups verifying insulin resistance 
that is ameliorated by leptin therapy. These findings confirm the hepatomegaly, 
hyperinsulinemia/ insulin resistance and hyperlipidemia seen in fatless mice and 
the effectiveness of leptin therapy while also suggesting that lipodystrophy, at 
least in the AZIP/F-1 mouse, is associated with delayed thrombosis independent 
of the lack of leptin. Lipodystrophic mice remain a useful model to study current 
epidemic metabolic disorders. 
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